

Date: February 1, 2022
To: Medical Care Providers, Healthcare and other Facilities
From: Thea Papasozomenos, MD, MPH, Assistant Health Officer

Please distribute to all providers and relevant staff in your facility

Health Update

COVID-19 Outpatient Therapeutics: updated locations for Sotrovimab, additional resources

On January 24, 2022, the Food and Drug Administration (FDA) revoked the Emergency Use Authorization (EUA) for two combination COVID-19 monoclonal antibody (mAb) therapy products, bamlanivimab plus etesevimab and casirivimab plus imdevimab (REGEN-COV), as they are not effective against the Omicron variant, the overwhelmingly dominant variant circulating in the US. The mAb therapy product, Sotrovimab, is effective against all currently circulating variants in California, including Omicron.

While more therapeutic product for outpatient use is becoming available, overall supply remains low, especially of Sotrovimab and Paxlovid – two of the most effective treatment options against Omicron.

Guidance for Stanislaus County Providers:

Options for COVID-19 outpatient therapeutics for Omicron:

General Information:

- The current order of preference, as recommended by the National Institutes of Health COVID-19 Treatment Guidelines, of therapeutics for nonhospitalized patients with mild to moderate COVID-19 who are at high risk of disease progression are: 1) Paxlovid; 2) Sotrovimab; 3) Remdesivir; and 4) Molnupiravir
- Please refer as needed to NIH guidelines for patient prioritization of outpatient COVID-19 therapies or preventive strategies during times of logistical or supply constraints (listed below).
- Please refer to the California Department of Public Health (CDPH) COVID-19 Treatments webpage (listed below) for ‘one-stop shopping’ for information on COVID-19 treatments, including links to COVID-19 treatment locators.
- Health and Human Services (HHS) COVID-19 Therapeutics Locator (listed below) currently provides locator information for the oral antivirals, Paxlovid and Molnupiravir, and the mAb for pre-exposure prophylaxis, Evusheld.

mAb, Sotrovimab:

- Authorized only for treatment in select patients, not for post-exposure prophylaxis; given as single IV infusion
- The National Infusion Center Association (NICA) website (listed below) provides locator information for mAb therapy currently, although the information provided for Sotrovimab is not up to date; as of February 1, 2022, the following sites are known to have Sotrovimab, per county information resources:
 - Elite Urgent Care: 1524 McHenry Ave., Ste. # 130 / Modesto, CA 95350
 - Kaiser-Modesto
 - Doctors Medical Center – Modesto
 - Pathways Healthcare: 190 S Oak Ave. / Oakdale, CA 95361
 - BAZ Allergy, Asthma, and Sinus Center: 1923 Coffee Rd., Ste. # 12 / Modesto, CA 95355
- Please reach out to these entities before any patient referral to confirm patient eligibility, product availability, and referral process.

(cont.) Options for COVID-19 outpatient therapeutics for Omicron:

Antivirals:

- Paxlovid: has a significant and complex drug-drug interaction potential, primarily due to the ritonavir component of its combination formulation of ritonavir-boosted nirmatrelvir. For additional guidance, refer to:
 - EUA fact sheet for Paxlovid
 - NIH COVID-19 Treatment Guidelines, Statement of Paxlovid Drug-Drug Interactions
 - University of Liverpool COVID-19 Drug Interactions webpage (listed below) for a drug interaction checker for Paxlovid (and Evusheld).
- Remdesivir: requires IV infusion for 3 consecutive days; available for purchase from AmerisourceBergen, which is currently limiting purchases to entities with hospital accounts. Health and Human Services (HHS) is working to expand purchase beyond hospital accounts. Address questions to AmerisourceBergen, c19therapies@amerisourcebergen.com.
- Molnupiravir: NIH COVID-19 Treatment Guidelines Panel recommends that Molnupiravir should only be used when Paxlovid, Sotrovimab, and Remdesivir are not available or cannot be given, as it has lower efficacy than the other options. It is currently available in designated pharmacies in Stanislaus County, and could offer benefit for some patients when other COVID-19 therapeutic products are not an option.

Additional Information:

- CDPH COVID-19 Treatments: <https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Treatments.aspx>
- HHS COVID-19 Therapeutics Locator: <https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/>
- National Infusion Center Association: <https://covid.infusioncenter.org/>
- University of Liverpool COVID-19 Drug Interactions: <https://www.covid19-druginteractions.org/>
- NIH COVID-19 Treatment Guidelines:
 - Statement on Paxlovid Drug-Drug Interactions: <https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-paxlovid-drug-drug-interactions/>
 - Statement on Therapies for High-Risk, Nonhospitalized Patients: <https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/>
 - Statement on Patient Prioritization for Outpatient Therapies: <https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-patient-prioritization-for-outpatient-therapies/>

CONFIDENTIALITY NOTICE: This message, including all attachments, is for the sole use of the intended recipient and may contain confidential and privileged information. If you are not the intended recipient, please contact the sender by reply fax immediately at 209-558-7286 or call 209-558-8804. Please destroy all copies of the original message and all attachments. Your cooperation is greatly appreciated.